HIV infection: Negative effects of viral replication during treatment;Infection par le VIH : effets délétères d'une réplication virale sous traitement

Antibiotiques

Volumn 10, Issue 2, 2008, Pages 73-80

  Poizot Martin, I ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

HIV infection; Immune reparation; Undetectable viruses; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MORBIDITY; MORTALITY; SURVIVAL; TREATMENT DURATION; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

EID: 53749097489     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antib.2008.02.001     Document Type: Article

References (60)

1. Mary-Krause M., Fichou J., Lanoy E., et al. L'infection à VIH après 10 ans de traitements antirétroviraux actifs dans la base de données hospitalière française sur l'infection à VIH (ANRS CO4 FHDH). BEH 46-47 (2007) 394-397
2. May M.T., Sterne J.A., Costagliola D., et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368 (2006) 451-458
3. Mellors J.W., Kingsley L.A., Rinaldo C.R., et al. Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 122 (1995) 573-579
4. Mellors J.W., Munoz A., Giorgi J.V., et al. Plasma viral load and CD4+ lymphocyte as pronostic markers of HIV-1 infection. Ann Intern Med 126 (1997) 946-954
5. O'brien W.A., Hartigan P.M., Martin D., et al. Changes in plasma HIV1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. N Engl J Med 334 (1996) 426-431
6. Wei X., Ghosh S.K., Taylor M.E., et al. Viral dynamics in human immunodeficiency virus type-1 infection. Nature 373 (1995) 117-122
7. Ho D.D., Neumann A.U., Perelson A.S., et al. Rapid turn-over of plasma virions and CD4 lymphocytes in HIV1-infection. Nature 373 (1995) 123-126
8. Pantaleo G., Graziosi C., and Fauci A.S. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328 (1993) 327-335
9. Prise en charge médicale des personnes infectées par le VIH. Rapport 2006. Recommandations du groupe d'experts. In: Yeni, editor. Medecine-Sciences, Flammarion.
10. Easterbrook P.J., Ives N., Waters A., et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to 400 copies/ml. AIDS 16 (2002) 1521-1527
11. Nebbia G., Booth C., Smith C., et al. The reproductibility and long term impact of viral load blips on virological and imunological outcomes of first-line HAART. HIV Med 7 (2006) 1-9
12. Sungkanuparph S., Overton E.T., Seyfried W., et al. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 41 (2005) 1333-1334
13. Jones L.E., and Perelson A.S. Transient viremia, plasma viral load and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 45 (2007) 483-493
14. Blankson J.N., Persaud D., Siliciano R.F., et al. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53 (2002) 557-593
15. Petitjean G., Al Tabaa, Tuaillon E., et al. Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology 4 (2007) 60
16. Pierson T., McArthur J., Siliciano R.F., et al. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18 (2000) 665-708
17. Roulet V., Satie A.P., Ruffault A., et al. Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro. Am J Pathol 169 (2006) 2094-2103
18. Wyatt C.M., and Klotman P.E. HIV-associated nephropathy in the era of antiretroviral therapy. Am J Med 120 (2007) 488-492
19. Belmonte L., Olmos M., Fanin A., et al. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART. AIDS 21 (2007) 2106-2108
20. Huang J., Wang R., Argyris E., et al. Cellular micro RNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 13 (2007) 1241-1247
21. Barre-Sinoussi F. Virologie fondamentale de l'infection VIH. In: Girard PM, Katlama C, Pialoux G., (Eds.). VIH édition, Doin; 2007. p. 3-10.
22. Nielsen M.H., Pedersen F.S., and Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology 2 (2005) 10
23. Weiss R.A. HIV receptors and cellular tropism. IUBMB Life 53 (2002) 201-205
24. Carcelain G, Aytran B. Mécanismes immunopathologiques de l'infection VIH. In: Girard PM, Katlama C, Pialoux G (Eds.). VIH édition, Doin; 2007. p. 23-42.
25. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
26. Sankaran S., Guadalupe M., Reay E., et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1 infected nonprogressers. Proc Natl Acad Sci U S A 102 (2005) 9860-9865
27. Guadalupe M., Sankaran S., George M.D., et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80 (2006) 8236-8247
28. Sankaran S., George M.D., Reav E., et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by imbalance between immune response and mucosal repair and regeneration. J Virol 82 (2008) 538-545
29. Chene G., Sterne J.A., May M., et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362 (2003) 679-686
30. Lohse N., Kronborg G., Gerstoft J., et al. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Clin Infect Dis 42 (2006) 136-144
31. 3. Antivir Ther 12 (2007) 941-947
32. Wood E., Yip B., Hogg R.S., et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 14 (2000) 1955-1960
33. Mocroft A., Phillips A.N., Gatell J., et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370 (2007) 407-413
34. Mocroft A., Phillips A.N., Ledergerber B., et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 20 (2006) 1141-1150
35. Wolbers M., Battegay M., Hirschel B., et al. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 12 (2007) 889-897
36. Moore R.D., and Keruly J.C. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44 (2007) 441-446
37. 3 or greater. J Acquir Immune Defic Syndr 45 (2007) 131-132
38. Smith C.J., Sabin C.A., Youle M.S., et al. Factors influencing increases in CD4 cell counts of HIV -positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 190 (2004) 1860-1868
39. Landay A., Da Silva B.A., King M.S., et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 44 (2007) 749-754
40. Landay A.L., Bettendorf D., Chan A., et al. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses 18 (2002) 95-102
41. Benito J.M., Lopez M., Lozano S., et al. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38 (2005) 373-381
42. Beran O., Holub M., Spala J., et al. CD38 expression on CD8+ T cells in human immunodeficiency virus-1 positive adults treated with HAART. Acta Virol 47 (2003) 121-124
43. Benito J.M., Lopez M., Lozano S., et al. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2 (2004) 227-233
44. Tilling R., Kinloch S., Goh L.E., et al. Parallel decline of CD8+/38++Tcells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 16 (2002) 589-596
45. Alatrakchi N., Duvivier C., Costagliola D., et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 19 (2005) 25-33
46. Karlsson A.C., Younger S.R., Martin J.N., et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 18 (2004) 981-989
47. Zaccarelli M., Tozzi V., Lorenzini P., et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 19 (2005) 1081-1089
48. Lohse N., Jorgensen L.B., Kronborg G., et al. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure. Antivir Ther 12 (2007) 909-917
49. Kantor R., Shafer R.W., Follansbee S., et al. Evolution of resistance to drugs in HIV-1 infected patients failing antiretroviral therapy. AIDS 18 (2004) 1503-1511
50. Stürmer M., Dauer B., Moesch M., et al. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antivir Ther 12 (2007) 25-30
51. Aleman S., Söderbärg K., Visco-Comandini U., et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16 (2002) 1039-1044
52. Metzner K.J., Allers K., and Rauch P. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 21 (2007) 703-711
53. Sedaghat A.R., Silicinao J.D., Brennan T.P., et al. Limits on replenishment of the resting CD4= T cell reservoir for HIV in patients on HAART. PLoS Pathog 3 (2007) e122
54. Ghosn J., Viard J.P., Katlama C., et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 18 (2004) 447-457
55. Van Marle G., Gill M.J., Kolodka D., et al. Compartimentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology 4 (2007) 87
56. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 4 (2007) 10-15
57. Poizot-Martin I, Coso D. Autres affections malignes chez les patients infectés par le VIH. In : Gastaut JA, Costello R, Poizot-Martin I. VIH/sida et cancers. Les affections malignes au cours de l'infection par le VIH. Ellipses édition; 2001. p. 119-42.
58. Gaya S.B.M., Rees A.J., Lechler R.I., et al. Malignant disease in patients with long-term renal transplants. Transplantation 59 (1995) 1705-1709
59. Meng Q., Walker D.M., Olivero O.A., et al. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci U S A 97 (2000) 12667-12671
60. Olivero O.A. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 48 (2007) 215-223